Speciality: Oncology
Description:
A warm welcome to all the medical professionals in this insightful session on Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC.
Managing ALK-positive Non-Small Cell Lung Cancer (NSCLC) presents unique challenges, especially when the disease metastasizes to the central nervous system (CNS). The brain-blood barrier often limits the efficacy of many systemic therapies, making CNS metastases a significant hurdle in treatment. Dr. Peush Bajpai and Dr. Ankur Nandan Varshney will delve into the complexities of this challenge, highlighting how newer generation ALK inhibitors are specifically designed to penetrate the CNS more effectively, offering better control of brain metastases and improving patient outcomes. This session will explore the latest strategies and best practices for addressing CNS involvement in ALK+ NSCLC.
Understanding the unique pharmacokinetic properties of CNS-penetrant ALK TKIs is crucial for optimizing patient management. This webinar will provide an in-depth look at current research, clinical trial data, and real-world experiences related to treating brain metastases in ALK+ NSCLC. Don't miss this opportunity to gain an overall knowledge on understanding the best practices in navigating the CNS challenge in ALK-positive NSCLC. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Inner Thoughts of Leonard Bernstein, the "Maestro".
2.
Mobile prostate cancer screening clinic can ID the disease in disadvantaged men
3.
No Survival Benefit Seen With Adjuvant Atezolizumab in TNBC
4.
Parents, teachers at Missouri school want answers after string of cancer diagnoses
5.
A promising medication could slow brain tumors in children.
1.
Future-Ready Cancer Screening: What Every Clinician Should Know in 2025
2.
Cancer Evolution and Therapeutic Resistance: Mechanisms, Clinical Insights, and Emerging Strategies
3.
Targeting Cancer Stem Cells in Solid Tumors: Mechanisms, Clinical Implications, and Therapeutic Advances
4.
Partial Gland Ablation in Prostate Cancer: Oncologic Outcomes in Intermediate-Risk Cases
5.
Generative AI for Adaptive Oncology Trial Design
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
5.
Current Scenario of Cancer- The Incidence of Cancer in Men
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation